Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19629002 | 0.85 | CYP3A4 (0.38) | GRM5CYP3A4CYP2C9ACACBCYP2D6 | |
| SCHEMBL23511786 | 0.84 | ALDH1A1 (0.41) | CYP3A4CYP2C9ACACBCYP2D6CYP2C19 | |
| SCHEMBL17729351 | 0.80 | APP (0.53) | CYP3A4CYP2C9CYP2D6CYP2C19KCNH2 | |
| SCHEMBL12016065 | 0.80 | LMNA (0.46) | GRM5CYP3A4CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL13981325 | 0.79 | GRM5 (0.56) | GRM5HTR2AFFAR1KCNH2 | |
| SCHEMBL18608233 | 0.78 | KCNH2 (0.51) | GRM5CYP3A4CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL21449243 | 0.78 | ACACB (0.42) | GRM5ACACBIDO1HTR2AFFAR1 | |
| SCHEMBL8141103 | 0.76 | ACACB (0.50) | ACACBIDO1FFAR1 | |
| SCHEMBL7038630 | 0.76 | CYP2C19 (0.54) | GRM5CYP3A4CYP2C9ACACBCYP2D6 | |
| SCHEMBL29084200 | 0.76 | APP (0.53) | CYP3A4CYP2C9CYP2D6CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-06-07 | — | — | US | disclosed |
| US-20220169652-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2022-06-02 | — | — | US | disclosed |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-12-07 | — | — | US | disclosed |
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-10-07 | — | — | US | disclosed |
| US-11091492-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-08-17 | — | — | US | disclosed |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-17 | — | — | US | disclosed |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| US-10934298-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | BIAL—BioTech Investments, Inc. (PT) | 2021-03-02 | — | — | US | disclosed |
| US-20200385390-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2020-12-10 | — | — | US | disclosed |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20170349599-A1 | IMIDAZO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - BIOTECH INVESTMENTS, INC. (PT) | 2017-11-23 | — | — | US | disclosed |
| US-20170334916-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-11-23 | — | — | US | disclosed |
| US-20170334916-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-11-23 | — | — | US | disclosed |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - BIOTECH INVESTMENTS, INC. (PT) | 2017-11-23 | — | — | US | disclosed |
| US-9732089-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732089-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170183354-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-06-29 | — | — | US | disclosed |
| US-20170183354-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334916-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | GRM5 382/4885CYP3A4 1441/4885CYP2C9 1008/4885 |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, PARK7 | GRM5 629/4885CYP3A4 1952/4885CYP2C9 1429/4885 |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | GRM5 1070/4885CYP3A4 2968/4885CYP2C9 2300/4885 |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | GBA1, PARK7, GAA | GRM5 173/4885CYP3A4 2197/4885CYP2C9 1436/4885 |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | GRM5 1070/4885CYP3A4 2968/4885CYP2C9 2300/4885 |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | GRM5 213/4885CYP3A4 1579/4885CYP2C9 1139/4885 |
| US-10934298-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | GBA1, GAA, PARK7 | GRM5 213/4885CYP3A4 2221/4885CYP2C9 1440/4885 |
| US-20170183354-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PNP, PNPO, TYMP | GRM5 1098/4885CYP3A4 1096/4885CYP2C9 1241/4885 |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | GRM5 646/4885CYP3A4 1671/4885CYP2C9 1471/4885 |
| US-20220169652-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | GRM5 382/4885CYP3A4 1441/4885CYP2C9 1008/4885 |
| US-20170349599-A1 | IMIDAZO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | GRM5 276/4885CYP3A4 1765/4885CYP2C9 1333/4885 |
| US-20200385390-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | GRM5 382/4885CYP3A4 1441/4885CYP2C9 1008/4885 |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | GRM5 668/4885CYP3A4 1784/4885CYP2C9 1504/4885 |
| US-11091492-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | GRM5 382/4885CYP3A4 1441/4885CYP2C9 1008/4885 |
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | GRM5 276/4885CYP3A4 1765/4885CYP2C9 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.